

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6160607

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SIRNA THERAPEUTICS, INC.	12/19/2017
RECEIVING PARTY DATA	
Name:	SIRNA THERAPEUTICS, INC.
Street Address:	300 THIRD STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15863578
CORRESPONDENCE DATA	
Fax Number:	(617)395-7070
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 395-7003
Email:	HRKPatents@LALaw.com
Correspondent Name:	LANDO & ANASTASI, LLP
Address Line 1:	60 STATE STREET, 23RD FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02109
ATTORNEY DOCKET NUMBER:	A2038-721820
NAME OF SUBMITTER:	HANNAH R. KOYFMAN
SIGNATURE:	/Hannah R. Koyfman/
DATE SIGNED:	06/18/2020
Total Attachments: 5	
source=Executed Assignment Merck to Sirna#page1.tif	
source=Executed Assignment Merck to Sirna#page2.tif	
source=Executed Assignment Merck to Sirna#page3.tif	
source=Executed Assignment Merck to Sirna#page4.tif	
source=Executed Assignment Merck to Sirna#page5.tif	

ASSIGNMENT


For good and valuable consideration, **Merck Sharp & Dohme Corp.**, a corporation of New Jersey having a place of business at 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907, sells, assigns and transfers to

Sirna Therapeutics, Inc.,

a corporation organized and existing under the laws of the state of Delaware, with offices at 300 Third Street, Cambridge, Massachusetts 02142, its successors, assigns and legal representatives, all hereinafter referred to as said Assignee, our entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for United States Patent entitled SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE filed on August 20, 2015 and assigned Serial No. 14/769,361; this assignment, including said application, and any and all continuations, continuations-in-part, and divisional applications, and any and all United States and foreign patents (including reissues, reexaminations, extensions), utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names, or in its own name, for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment, the effectiveness of this assignment including as of the filing date of the above-identified application and any applications from which the above-identified application claims benefit of.

Merck Sharp & Dohme Corp.

12/19/2007
Date

 (Seal)
NAME: John C. Todaro


TITLE: Managing Counsel

Said Assignee does hereby acknowledge and accept the above sale, assignment and transfer of all the rights, title and interest enumerated above, including but not limited to the right to priority and the right to sue for past infringement.

By: SIRNA THERAPEUTICS, INC.

December 19, 2017

Date


Signature

Steven A. Bossone

Printed Name of Signor

Vice President, Intellectual Property

Title/Authority of Signor

MERCK & CO., INC.

CERTIFICATION

I, Katie E. Fedosz, Senior Assistant Secretary of Merck & Co., Inc. (the "Company"), a corporation duly organized and existing under the laws of the State of New Jersey, United States of America, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended and readopted the Board of Directors of said Company at a meeting thereof duly called and held on May 23, 2017, at which a quorum of Directors was present.


IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 24th day of May, 2017.


Senior Assistant Secretary

(SEAL)

United States of America)
State of New Jersey) SS
County of Union)

Subscribed and sworn to before me on this 24th day of May, 2017.


Notary Public

SANDRA MARIE MCFADDEN
NOTARY PUBLIC, STATE OF NEW JERSEY
MY COMMISSION EXPIRES JANUARY 18, 2020

General Corporate Resolution #5

PATENT MATTERS

RESOLVED, that any of the following:

Kenneth C. Frazier – Chairman, President and Chief Executive Officer
Michael J. Holston – Executive Vice President and General Counsel
William Krovatin – Senior Vice President and Assistant General Counsel
Gerard M. Devlin, Jr. – Managing Counsel, IP Litigation
Catherine D. Fitch – Managing Counsel, Patents
Gloria Fuentes – Managing Counsel, Patents
J.J.L. Mestrom – Managing Counsel, Animal Health IP
John C. Todaro – Managing Counsel, Patents
James Horgan – Assistant Managing Counsel, European Patents
Cynthia A. Francisco – Director, Asset Management

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:

Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.

